The use of agomelatine in OCD: effects on the motivational aspects and dysregulated circadian rhythms

Bibliography

• Nolen WA. World Health Organization places psychiatry high on the agenda, also consequences for the Netherlands. Ned Tijdschr Geneeskd 2002;146(7):297-9
   PubMedGoogle Scholar
• Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62(6):617-27
   PubMed Web of Science ®Google Scholar
• Nestadt G, Samuels J, Riddle M, et al. A family study of obsessive-compulsive disorder. Arch Gen Psychiatry 2000;57(4):358-63
   PubMed Web of Science ®Google Scholar
• Valleni-Basile LA, Garrison CZ, Jackson KL, et al. Frequency of obsessive-compulsive disorder in a community sample of young adolescents. J Am Acad Child Adolesc Psychiatry 1994;33(6):782-91
   PubMed Web of Science ®Google Scholar
• Jenike MA. Clinical practice. Obsessive-compulsive disorder. N Engl J Med 2004;350(3):259-65
   PubMed Web of Science ®Google Scholar
• Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990;47(6):577-85
   PubMed Web of Science ®Google Scholar
• Pallanti S, Hollander E, Bienstock C, et al. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002;5(2):181-91
   PubMed Web of Science ®Google Scholar
• Dell’osso B, Mundo E, Marazziti D, et al. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series. J Psychopharmacol 2008;22(2):210-13
   PubMed Web of Science ®Google Scholar
• Fornaro M, Gabrielli F, Albano C, et al. Obsessive-compulsive disorder and related disorders: a comprehensive survey. Ann Gen Psychiatry 2009;8:13
   PubMedGoogle Scholar
• Perugi G, Akiskal HS, Pfanner C, et al. The clinical impact of bipolar and unipolar affective comorbidity on obsessive-compulsive disorder. J Affect Disord 1997;46(1):15-23
   PubMed Web of Science ®Google Scholar
• Chen YW, Dilsaver SC. Comorbidity for obsessive-compulsive disorder in bipolar and unipolar disorders. Psychiatry Res 1995;59(1-2):57-64
   PubMed Web of Science ®Google Scholar
• Centorrino F, Hennen J, Mallya G, et al. Clinical outcome in patients with bipolar I disorder, obsessive compulsive disorder or both. Hum Psychopharmacol 2006;21(3):189-93
   PubMed Web of Science ®Google Scholar
• Hantouche EG, Angst J, Demonfaucon C, et al. Cyclothymic OCD: a distinct form? J Affect Disord 2003;75(1):1-10
   PubMed Web of Science ®Google Scholar
• Perugi G, Toni C, Frare F, et al. Obsessive-compulsive-bipolar comorbidity: a systematic exploration of clinical features and treatment outcome. J Clin Psychiatry 2002;63(12):1129-34
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Fineberg NA, Drummond LM, et al. Delayed sleep phase in severe obsessive-compulsive disorder: a systematic case-report survey. CNS Spectr 2008;13(5):406-13
   PubMed Web of Science ®Google Scholar
• Paterson JL, Reynolds AC, Ferguson SA, et al. Sleep and obsessive-compulsive disorder (OCD). Sleep Med Rev 2013;17(6):465-74
   PubMed Web of Science ®Google Scholar
• Alfano CA, Kim KL. Objective sleep patterns and severity of symptoms in pediatric obsessive compulsive disorder: a pilot investigation. J Anxiety Disord 2011;25(6):835-9
   PubMed Web of Science ®Google Scholar
• Hegerl U, Stein M, Mulert C, et al. EEG-vigilance differences between patients with borderline personality disorder, patients with obsessive-compulsive disorder and healthy controls. Eur Arch Psychiatry Clin Neurosci 2008;258(3):137-43
   PubMed Web of Science ®Google Scholar
• Papadimitriou GN, Linkowski P. Sleep disturbance in anxiety disorders. Int Rev Psychiatry 2005;17(4):229-36
   PubMed Web of Science ®Google Scholar
• Voderholzer U, Riemann D, Huwig-Poppe C, et al. Sleep in obsessive compulsive disorder: polysomnographic studies under baseline conditions and after experimentally induced serotonin deficiency. Eur Arch Psychiatry Clin Neurosci 2007;257(3):173-82
   PubMed Web of Science ®Google Scholar
• Kluge M, Schüssler P, Dresler M, et al. Sleep onset REM periods in obsessive compulsive disorder. Psychiatry Res 2007;152(1):29-35
   PubMed Web of Science ®Google Scholar
• Insel TR, Gillin JC, Moore A, et al. The sleep of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1982;39(12):1372-7
   PubMed Web of Science ®Google Scholar
• Hohagen F, Lis S, Krieger S, et al. Sleep EEG of patients with obsessive-compulsive disorder. Eur Arch Psychiatry Clin Neurosci 1994;243(5):273-8
   PubMed Web of Science ®Google Scholar
• Rapoport J, Elkins R, Langer DH, et al. Childhood obsessive-compulsive disorder. Am J Psychiatry 1981;138(12):1545-54
   PubMed Web of Science ®Google Scholar
• Bobdey M, Fineberg N, Gale TM, et al. Reported sleep patterns in obsessive compulsive disorder (OCD). Int J Psychiatry Clin Pract 2002;6(1):15-21
   PubMed Web of Science ®Google Scholar
• Turner J, Drummond LM, Mukhopadhyay S, et al. A prospective study of delayed sleep phase syndrome in patients with severe resistant obsessive-compulsive disorder. World Psychiatry 2007;6(2):108-11
   PubMed Web of Science ®Google Scholar
• Schubert JR, Coles ME. Obsessive-compulsive symptoms and characteristics in individuals with delayed sleep phase disorder. J Nerv Ment Dis 2013;201(10):877-84
   PubMed Web of Science ®Google Scholar
• Monteleone P, Catapano F, Del Buono G, et al. Circadian rhythms of melatonin, cortisol and prolactin in patients with obsessive-compulsive disorder. Acta Psychiatr Scand 1994;89(6):411-15
   PubMed Web of Science ®Google Scholar
• Catapano F, Monteleone P, Fuschino A, et al. Melatonin and cortisol secretion in patients with primary obsessive-compulsive disorder. Psychiatry Res 1992;44(3):217-25
   PubMed Web of Science ®Google Scholar
• Kluge M, Schüssler P, Künzel HE, et al. Increased nocturnal secretion of ACTH and cortisol in obsessive compulsive disorder. J Psychiatr Res 2007;41(11):928-33
   PubMed Web of Science ®Google Scholar
• Altemus M, Pigott T, Kalogeras KT, et al. Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder. Arch Gen Psychiatry 1992;49(1):9-20
   PubMed Web of Science ®Google Scholar
• Chappell P, Leckman J, Goodman W, et al. Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette’s syndrome: comparison to obsessive compulsive disorder and normal controls. Biol Psychiatry 1996;39(9):776-83
   PubMed Web of Science ®Google Scholar
• Murray G, Nicholas CL, Kleiman J, et al. Nature’s clocks and human mood: the circadian system modulates reward motivation. Emotion 2009;9(5):705-16
   PubMed Web of Science ®Google Scholar
• Dijk DJ, von Schantz M. Timing and consolidation of human sleep, wakefulness, and performance by a symphony of oscillators. J Biol Rhythms 2005;20(4):279-90
   PubMed Web of Science ®Google Scholar
• Hasler BP, Clark DB. Circadian misalignment, reward-related brain function, and adolescent alcohol involvement. Alcohol Clin Exp Res 2013;37(4):558-65
   PubMed Web of Science ®Google Scholar
• Monteleone P, Maj M. The circadian basis of mood disorders: recent developments and treatment implications. Eur Neuropsychopharmacol 2008;18(10):701-11
   PubMed Web of Science ®Google Scholar
• Soreca I. Circadian rhythms and sleep in bipolar disorder: implications for pathophysiology and treatment. Curr Opin Psychiatry 2014;27(6):467-71
   PubMed Web of Science ®Google Scholar
• Boudebesse C, Geoffroy PA, Bellivier F, et al. Correlations between objective and subjective sleep and circadian markers in remitted patients with bipolar disorder. Chronobiol Int 2014;31(5):698-704
   PubMed Web of Science ®Google Scholar
• Geoffroy PA, Boudebesse C, Bellivier F, et al. Sleep in remitted bipolar disorder: a naturalistic case-control study using actigraphy. J Affect Disord 2014;158:1-7
   PubMed Web of Science ®Google Scholar
• Robillard R, Naismith SL, Rogers NL, et al. Sleep-wake cycle and melatonin rhythms in adolescents and young adults with mood disorders: comparison of unipolar and bipolar phenotypes. Eur Psychiatry 2013;28(7):412-16
   PubMed Web of Science ®Google Scholar
• Ruscio AM, Stein DJ, Chiu WT, et al. The epidemiology of obsessive-compulsive disorder in the national comorbidity survey replication. Mol Psychiatry 2010;15(1):53-63
   PubMed Web of Science ®Google Scholar
• Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007;64(5):543-52
   PubMed Web of Science ®Google Scholar
• Terracciano A, Sanna S, Uda M, et al. Genome-wide association scan for five major dimensions of personality. Mol Psychiatry 2010;15(6):647-56
   PubMed Web of Science ®Google Scholar
• Robillard R, Naismith SL, Rogers NL, et al. Delayed sleep phase in young people with unipolar or bipolar affective disorders. J Affect Disord 2013;145(2):260-3
   PubMed Web of Science ®Google Scholar
• Zlotos DP. Recent advances in melatonin receptor ligands. Arch Pharm (Weinheim) 2005;338(5-6):229-47
   PubMed Web of Science ®Google Scholar
• Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003;306(3):954-64
   PubMed Web of Science ®Google Scholar
• de Bodinat C, Guardiola-Lemaitre B, Mocaër E, et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 2010;9(8):628-42
   PubMed Web of Science ®Google Scholar
• Popoli M. Agomelatine: innovative pharmacological approach in depression. CNS Drugs 2009;23(Suppl 2):27-34
   PubMedGoogle Scholar
• Agency EM. CHMP Assessment for Valdoxan, D.R. EMEA/655251/2008, Editor. London. 20 November 2008.
   Google Scholar
• Skene DJ, Arendt J. Human circadian rhythms: physiological and therapeutic relevance of light and melatonin. Ann Clin Biochem 2006;43(Pt 5):344-53
   PubMedGoogle Scholar
• Landolt HP, Meier V, Burgess HJ, et al. Serotonin-2 receptors and human sleep: effect of a selective antagonist on EEG power spectra. Neuropsychopharmacology 1999;21(3):455-66
   PubMed Web of Science ®Google Scholar
• Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999;19(1):67-85
   PubMed Web of Science ®Google Scholar
• Fornaro M. Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder: a 3 month follow-up case series. Ann Gen Psychiatry 2011;10(1):5
   PubMed Web of Science ®Google Scholar
• Crippa JA, Hallak JE, Zuardi AW, et al. Agomelatine in the treatment of social anxiety disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010;34(7):1357-8
   PubMed Web of Science ®Google Scholar
• Fornaro M. Agomelatine in the treatment of panic disorder. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(1):286-7
   PubMed Web of Science ®Google Scholar
• Hanoun N, Mocaër E, Boyer PA, et al. Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brain. Neuropharmacology 2004;47(4):515-26
   PubMed Web of Science ®Google Scholar
• Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006;59(12):1116-27
   PubMed Web of Science ®Google Scholar
• Banasr M, Soumier A, Hery M, et al. Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol Psychiatry 2006;59(11):1087-96
   PubMed Web of Science ®Google Scholar
• Conboy L, Tanrikut C, Zoladz PR, et al. The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats. Int J Neuropsychopharmacol 2009;12(3):329-41
   PubMed Web of Science ®Google Scholar
• Zajecka J, Schatzberg A, Stahl S, et al. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2010;30(2):135-44
   PubMed Web of Science ®Google Scholar
• Zupancic M, Guilleminault C. Agomelatine: a preliminary review of a new antidepressant. CNS Drugs 2006;20(12):981-92
   PubMed Web of Science ®Google Scholar
• Howland RH. Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults. Neuropsychiatr Dis Treat 2009;5:563-76
   PubMed Web of Science ®Google Scholar
• Papp M, Litwa E, Gruca P, et al. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav Pharmacol 2006;17(1):9-18
   PubMed Web of Science ®Google Scholar
• Barden N, Shink E, Labbé M, et al. Antidepressant action of agomelatine (S 20098) in a transgenic mouse model. Prog Neuropsychopharmacol Biol Psychiatry 2005;29(6):908-16
   PubMedGoogle Scholar
• Millan MJ, Brocco M, Gobert A, et al. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl) 2005;177(4):448-58
   PubMed Web of Science ®Google Scholar
• Fornaro M, Prestia D, Colicchio S, et al. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol 2010;8(3):287-304
   PubMed Web of Science ®Google Scholar
• Di Giannantonio M, Di Iorio G, Guglielmo R, et al. Major depressive disorder, anhedonia and agomelatine: an open-label study. J Biol Regul Homeost Agents 2011;25(1):109-14
   PubMed Web of Science ®Google Scholar
• Laux G, Group VS. The antidepressant agomelatine in daily practice: results of the non-interventional study VIVALDI. Pharmacopsychiatry 2012;45(7):284-91
   PubMed Web of Science ®Google Scholar
• Stein DJ, Ahokas A, Albarran C, et al. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. J Clin Psychiatry 2012;73(7):1002-8
   PubMed Web of Science ®Google Scholar
• Stein DJ, Picarel-Blanchot F, Kennedy SH. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. Hum Psychopharmacol 2013;28(2):151-9
   PubMed Web of Science ®Google Scholar
• Stein DJ, Ahokas A, Márquez MS, et al. Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study. J Clin Psychiatry 2014;75(4):362-8
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006;16(2):93-100
   PubMed Web of Science ®Google Scholar
• De Berardis D, Serroni N, Campanella D, et al. A case of obsessive-compulsive disorder successfully treated with agomelatine monotherapy. J Clin Psychopharmacol 2012;32(2):289-90
   PubMed Web of Science ®Google Scholar
• De Berardis D, Serroni N, Marini S, et al. Agomelatine augmentation of escitalopram therapy in treatment-resistant obsessive-compulsive disorder: a case report. Case Rep Psychiatry 2012;2012:642752
   PubMedGoogle Scholar
• Antoniadis D, Floros GD, Nikolaidis N, et al. Response to agomelatine: treatment of an obsessive skin picking episode. Ann Clin Psychiatry 2013;25(3):228-9
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Guelfi JD, Perdrizet-Chevallier C, et al. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord 2007;9(6):628-35
   PubMed Web of Science ®Google Scholar
• Eppel AB. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord 2008;10(6):749-50
   PubMed Web of Science ®Google Scholar
• Fornaro M, McCarthy MJ, De Berardis D, et al. Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study. Neuropsychiatr Dis Treat 2013;9:243-51
   PubMed Web of Science ®Google Scholar
• Tiuvina NA, Smirnova VN. A comparative evaluation of the efficacy of valdoxan (agomelatine) in recurrent depression and bipolar affective disorder. Zh Nevrol Psikhiatr Im S S Korsakova 2012;112(11 Pt 2):53-60
   PubMedGoogle Scholar
• Monteleone P, Catapano F, Tortorella A, et al. Plasma melatonin and cortisol circadian patterns in patients with obsessive-compulsive disorder before and after fluoxetine treatment. Psychoneuroendocrinology 1995;20(7):763-70
   PubMed Web of Science ®Google Scholar
• Lange KW, Lange KM, Hauser J, et al. Circadian rhythms in obsessive-compulsive disorder. J Neural Transm 2012;119(10):1077-83
   PubMed Web of Science ®Google Scholar
• da Rocha FF, Correa H. Is circadian rhythm disruption important in obsessive-compulsive disorder (OCD)? A case of successful augmentation with agomelatine for the treatment of OCD. Clin Neuropharmacol 2011;34(4):139-40
   PubMed Web of Science ®Google Scholar
• Tzavellas E, Karaiskos D, Ilias I, et al. Agomelatine augmentation in obsessive compulsive disorder: a preliminary report. Psychiatriki 2014;25(3):179-84
   Google Scholar
• Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs 2010;24(6):479-99
   PubMed Web of Science ®Google Scholar
• Quera-Salva MA, Hajak G, Philip P, et al. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol 2011;26(5):252-62
   PubMed Web of Science ®Google Scholar
• Montejo A, Majadas S, Rizvi SJ, et al. The effects of agomelatine on sexual function in depressed patients and healthy volunteers. Hum Psychopharmacol 2011;26(8):537-42
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Emsley R, Rembry S, et al. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70(8):1128-37
   PubMed Web of Science ®Google Scholar
• Kozian R, Syrbe G. QTc prolongation during treatment with agomelatine. Psychiatr Prax 2010;37(8):405-7
   PubMed Web of Science ®Google Scholar
• Stahl SM, Fava M, Trivedi MH, et al. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry 2010;71(5):616-26
   PubMed Web of Science ®Google Scholar
• Gahr M, Freudenmann RW, Connemann BJ, et al. Agomelatine and hepatotoxicity: implications of cumulated data derived from spontaneous reports of adverse drug reactions. Pharmacopsychiatry 2013;46(6):214-20
   PubMed Web of Science ®Google Scholar
• Haack M, Mullington JM. Sustained sleep restriction reduces emotional and physical well-being. Pain 2005;119(1-3):56-64
   PubMed Web of Science ®Google Scholar
• Durmer JS, Dinges DF. Neurocognitive consequences of sleep deprivation. Semin Neurol 2005;25(1):117-29
   PubMed Web of Science ®Google Scholar
• Martinet L, Guardiola-Lemaitre B, Mocaer E. Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent. Pharmacol Biochem Behav 1996;54(4):713-18
   PubMed Web of Science ®Google Scholar
• Armstron SM, McNulty OM, Guardiola-Lemaitre B, et al. Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS). Pharmacol Biochem Behav 1993;46(1):45-9
   PubMed Web of Science ®Google Scholar
• Krauchi K, Cajochen C, Möri D, et al. Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol 1997;272(4 Pt 2):R1178-88
   PubMed Web of Science ®Google Scholar
• Leproult R, Van Onderbergen A, L’hermite-Balériaux M, et al. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol (Oxf) 2005;63(3):298-304
   PubMed Web of Science ®Google Scholar